publication date: Jun. 26, 2020
Issue 26 - Jun. 26, 2020
  • Participation by minority racial, ethnic groups in NCI-funded trials nearly doubles in 20 years

    The proportion of racial and ethnic minority patients in NCI-funded clinical trials has nearly doubled over two decades—from 14% in 1999 to 25% in 2019, according to data from NCI’s National Clinical Trials Network and the NCI Community Oncology Research Program.

  • The Cancer Letter’s paywall is returning

    When the COVID-19 crisis began, The Cancer Letter made the decision to take down our paywall, and provide coverage of the pandemic free of charge “until this crisis is resolved” (The Cancer LetterApril 3, 2020).

  • AACR session on disparities points to the new consensus: Being woke is not enough

    The name of the session was a message in and of itself: “Racism and Racial Inequalities in Cancer Research.”

  • NCI seeks applications to build research capacity for COVID-19 serology and immunology

    NCI has issued two Requests for Applications and a Request for Proposals focused on COVID-19 serology and immunology.

  • Collins: It’s unknown whether COVID-19 antibody-positive test means protection against reinfection

    In March, as SARS-CoV-2 spread rapidly across the United States, cancer researchers scrambled to find clues about the virus and ways to mitigate its damage.

  • Guest Editorial

    To expedite progress against COVID-19, a public-private “accelerator” taps into real-world data

    Real-world data is everywhere. During the COVID-19 global pandemic, we are literally generating, and collecting, real-world data every single day—from electronic health records, insurance claims, patient registries, and a myriad of other sources. But the question remains: how do we use this data to better understand, prevent, and treat this disease?

  • In Brief

    • Kids v Cancer urges Congress to permanently reauthorize pediatric voucher program
    • UAMS Winthrop P. Rockefeller Cancer Institute joins Kiyatec clinical study
  • AACR Briefs

    • David A. Tuveson elected AACR president-elect for 2020-2021
    • James R. Downing receives inaugural AACR-St. Baldrick’s Foundation award for pediatric cancer research
    • TCGA founding members and project team receive AACR 2020 Team Science Awards
    • Jedd D. Wolchok receives AACR-Joseph H. Burchenal Award for clinical cancer research
    • Cigall Kadoch receives AACR Award for basic cancer research
    • Lisa A. Newman receives AACR-Minorities in Cancer Research Jane Cooke Wright Lectureship
    • Patricia S. Steeg receives 2020 AACR-Women in Cancer Research Charlotte Friend Lectureship
    • Benjamin F. Cravatt receives 2020 AACR Award for chemistry in cancer research
    • Christopher I. Amos receives 2020 AACR-American Cancer Society Award for research in cancer epidemiology and prevention
    • Michael Karin receives 2020 AACR-G.H.A. Clowes Award for basic cancer research
    • Michelle M. Le Beau receives AACR-Margaret Foti Award for leadership and achievements in cancer research
    • Barbara J. Wold receives AACR-Irving Weinstein Foundation lectureship
    • Luis A. Diaz receives AACR-Waun Ki Hong Award
    • Tyler Jacks receives AACR Princess Takamatsu Memorial Lectureship
    • Phillip A. Sharp receives award for lifetime achievement in cancer research
    • Herbst, Lowy, Majima, Spears, receive AACR distinguished public service award
    • AACR names fellows of the AACR Academy class of 2020
    • Charles L. Sawyers named AACR Academy president-elect
    • Steven A. Rosenberg receives AACR-CRI Lloyd J. Old Award in cancer immunology
    • John E. Dick receives 2020 Pezcoller Foundation-AACR International Award for Extraordinary Achievement in Cancer Research
  • TCCL Logo

  • Clinical Roundup

    • FDA pilot program to communicate patient reported outcomes from cancer clinical trials
    • Black cancer patients better represented in publicly-funded clinical trials
    • AI dual-stain approach improved accuracy, efficiency of cervical cancer screening in NCI study
    • IPATential150 study meets rPFS primary endpoint in mCRPC
    • City of Hope, TGen study shows T cells can predict how patients respond to immunotherapy
    • Liquid biopsies using urine and plasma help detect NSCLC
    • Online program significantly improves insomnia in adolescent and young adult cancer survivors
    • Study: LifeTracDx blood test shows positive results in detection of early stage cancer in solid tumors
  • Drugs & Targets

    • FDA approves Keytruda for cutaneous squamous cell carcinoma
    • Selinexor receives FDA approval for relapsed/refractory diffuse large B-cell lymphoma
    • Oral relugolix NDA accepted for Priority Review by FDA
    • Keytruda approved in China for second-line treatment of locally advanced or metastatic ESCC indication

Copyright (c) 2020 The Cancer Letter Inc.